Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 9/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25073359 | 0.88 | L3MBTL1 (0.43) | PTPN11CSNK2A2CSNK2A1NPSR1MAP4K4 | |
| SCHEMBL25073309 | 0.88 | THRB (0.43) | PTPN11CSNK2A2CSNK2A1ACLYPTK2B | |
| SCHEMBL25072760 | 0.87 | KDM4E (0.47) | PTPN11CSNK2A2CSNK2A1ACLYPTK2B | |
| SCHEMBL25073104 | 0.85 | KDM4E (0.46) | CSNK2A2CSNK2A1ACLY | |
| SCHEMBL25734411 | 0.84 | PTPN11 (0.40) | PTPN11CSNK2A2CSNK2A1ACLYSMN1; SMN2 | |
| SCHEMBL25072766 | 0.84 | PTPN11 (0.42) | PTPN11CSNK2A2CSNK2A1NPSR1MAP4K4 | |
| SCHEMBL25072610 | 0.83 | SSTR5 (0.41) | PTPN11SMN1; SMN2METAP2 | |
| SCHEMBL25073194 | 0.83 | XDH (0.41) | PTPN11CSNK2A2CSNK2A1NPSR1MAP4K4 | |
| SCHEMBL25073256 | 0.83 | MKNK1 (0.40) | PTPN11CSNK2A2CSNK2A1ACLYNPSR1 | |
| SCHEMBL25072757 | 0.81 | PTPN11 (0.41) | PTPN11CSNK2A2CSNK2A1ACLYSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | CMA1 816/4885PTPN11 3612/4885CSNK2A2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.